Neutrophils and monocytes in cattle express a novel class of immunoglobulin Fc receptor, specific for bovine IgG2 (bIgG2), termed bFc␥2R. In cows, the ability of neutrophils to kill immunoglobulin-opsonized microorganisms appears to depend largely on this subclass, whose interaction with bFc␥2R initiates the killing process. bFc␥2R is a transmembrane glycoprotein consisting of two extracellular immunoglobulin-like domains, followed by a 19-amino acid membrane-spanning region and a short cytoplasmic tail. Although related to other mammalian Fc␥Rs, bFc␥2R belongs to a novel gene family that includes the human killer cell inhibitory receptor and Fc␣RI (CD89) proteins. We have shown previously (Morton, H. C., van Zandbergen, G., van Kooten, C., Howard, C. J., van de Winkel, J. G., and Brandtzaeg, P. (1999) J. Exp. Med. 189, 1715-1722) that like these proteins (and unlike other Fc␥Rs), bFc␥2R binds bIgG2 via the membrane-distal extracellular domain 1 (EC1). In this present study, we introduced mutations into the predicted loop regions of the EC1 domain and assayed the resulting bFc␥2R mutants for their ability to bind bIgG2. Our results indicated that the bIgG2 binding site lies within the predicted F-G loop region of the EC1 domain. Furthermore, single amino acid mutational analysis of this region identified Phe-82 and Trp-87 as being critical for bIgG2 binding.
been isolated, of which three are considered homologues to Fc␥RI (CD64), Fc␥RII (CD32), and Fc␥RIII (CD16) expressed by many other mammalians including humans (7, 9 -11) . A homologue of the MHC class I-like FcR, FcRn, which is responsible for maternal transfer of IgG in humans, mice, and rats, is also found in cattle (12) . In addition, there is a novel type of Fc␥R specific for bIgG2, termed bFc␥2R (13) . This FcR is genetically more closely related to a novel family of human proteins that includes Fc␣RI (CD89) and the KIR, monocyte/ macrophage Ig-like receptor, and Ig-like transcripts/LIR families of receptors, which all probably arose by a series of duplication events from a single ancestral gene (14) .
To date little is known about the respective roles of the bIgG subclasses and the different cattle Fc␥Rs in the triggering of immune effector functions. In terms of humoral immunity, it has been reported that bIgG1 is a better activator of complement (at least in vitro), which may be linked to the observation that most breeds of cattle have a higher serum concentration of bIgG1 than bIgG2 (3, 15) . Importantly, however, when cellmediated immune reactions were examined in cattle, bIgG2 seemed to perform at least as well as, and sometimes even better than, bIgG1. For example, in an in vitro assay system that measured the ability of bovine macrophages and neutrophils to kill Ig-opsonized Mycoplasma bovis, both isotypes performed equally when macrophages were employed as effector cells. However, when neutrophils were used, only bIgG2 was able to promote effective killing (16) . These results could be explained in part by the observation that bovine monocytes and macrophages express Fc␥Rs for both bIgG isotypes, whereas neutrophils express high numbers of receptors for bIgG2 but few or none for bIgG1 (17) . Thus, although it is still difficult to assess the biological role of the bovine homologues of Fc␥RI, Fc␥RII, and Fc␥RIII, due partly to the lack of specific monoclonal antibodies (mAbs), it is clear that bIgG2 and its receptor on neutrophils and macrophages, bFc␥2R, is an important triggering molecule for cellular effector functions in cattle.
bFc␥2R consists of two extracellular Ig-like domains, followed by a transmembrane region and a short cytoplasmic tail. Uniquely, for an Fc␥R, bFc␥2R has been shown to bind bIgG2 via its membrane-distal EC1 domain (18) . All other Fc␥Rs so-far characterized bind IgG via the membrane proximal EC2 domain (19, 20) . However, it now appears that ligand binding via the EC1 domain may be a typical characteristic of many other members of the gene family to which bFc␥2R belongs, including CD89, KIR, and LIR-1 (18, 21, 22) .
In this study we have used site-directed mutagenesis to identify regions of the EC1 domain of bFc␥2R involved in the binding of bIgG2. Our results showed that the bIgG2 binding site lies within the putative F-G loop of the EC1 domain. Moreover, Phe-82 and Trp-87 were identified as critical for binding. This site is analogous to the IgA binding site of CD89 and the UL18 binding site of LIR-1 but distinct from the MHC I binding site of the KIRs (21) (22) (23) . These results may contribute to a better understanding of the evolution and function of this novel family of receptors.
MATERIALS AND METHODS
Cell Culture-COS-1 cells were maintained in Dulbecco's modified Eagle's medium (BioWhittaker, Walkserville, MD) supplemented with 10% fetal calf serum, 1 mM L-glutamine, and 50 g/ml gentamycin (Life Technologies, Inc.).
cDNAs and mAbs-cDNA for bFc␥2R has been described previously (13) . The bFc␥2R mAb CC-G24 (murine IgM) was generated by immunizing mice with bFc␥2R protein purified from bovine leukocytes, and the specificity was confirmed by staining COS-7 cells transfected with cDNA encoding bFc␥2R or bFc␥RII. 2 Construction of Mutated bFc␥2R cDNAs-Mutations were introduced by overlap extension PCR with appropriate synthetic oligonucleotides. In all cases, mutations were introduced into the cDNAs that resulted in the replacement of the amino acid(s) of interest with Ala. The integrity of all mutant cDNAs was confirmed by sequence analysis. Mutant bFc␥2R cDNAs were cloned into the pCDNA3 mammalian expression vector (Invitrogen) prior to transfection. The pCMV-GFP plasmid, which directed the expression of GFP, was constructed by inserting the CMV promoter region from pCDNA3 into the multiple cloning site of the pEGFP-1 vector (CLONTECH, Palo Alto, CA).
Transfections-COS-1 cells were transiently transfected with 1 g of bFc␥2R cDNA constructs by means of Fugene 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. Cells to be used for Ig binding assays were co-transfected with 0.05 g of the pCMV-GFP plasmid, in addition to the bFc␥2R constructs. Cells were incubated at 37°C in a humidified CO 2 atmosphere for 48 h prior to harvesting.
Isolation of Bovine Neutrophils-Bovine polymorphonuclear neutrophils were purified from peripheral blood of cattle by density centrifugation on lymphoprep (Nycomed, Oslo, Norway), followed by isotonic lysis of the red blood cells.
Ig Binding Assays-Uncoated magnetic M-450 Dynabeads (Dynal, Oslo, Norway) were coated, according to the manufacturer's instructions, with bIgG2 that was purified as described previously (13) . COS-1 cells were first enriched for those that had taken up DNA during the transfection procedure, as measured by expression of GFP. Therefore, binding assays were performed as follows: 0.5 ϫ 10 5 GFP ϩ COS-1 cells (which had also been co-transfected with a bFc␥2R construct) were purified in a FACSVantage cell sorter (Becton Dickinson, San Jose, CA) and mixed with bIgG2-coated Dynabeads in a final volume of 50 l per well in V-bottomed microtitre plates. Following a 20-min incubation at room temperature, the plate was spun at 50 ϫ g for 1 min and incubated for an additional 45 min at room temperature. Cells and beads were then carefully resuspended and examined for the presence of rosettes in a Nikon Eclipse E800 microscope, combining ordinary light and fluorescence. Rosettes were defined as GFP ϩ cells binding four or more Ig-coated beads; at least 200 GFP ϩ COS-1 cells were counted for each determination. For blocking studies, the cells were incubated with mAb CC-G24 for 30 min at 4°C prior to the addition of Ig-coated beads.
FACS Analysis-To assess expression of the bFc␥2R mutants at the cell surface, COS-1 cells (transfected with only the bFc␥2R cDNAs and not the GFP construct) or bovine neutrophils were washed twice with FACS buffer (phosphate-buffered saline/0.5% bovine serum albumin/ 0.02% azide) and incubated with mAb CC-G24 to bFc␥2R, or an irrelevant murine IgM mAb as control, for 1 h at 4°C. Cells were next washed twice with FACS buffer and incubated for 1 h at 4°C with goat anti-mouse IgM-FITC conjugate (Southern Biotechnology). After washing twice with FACS buffer, cells were analyzed on a FACScan (Becton Dickinson). To examine the binding of small soluble bIgG2 complexes in solution, transfected COS-1 cells or bovine neutrophils were incubated with bIgG2 heat-aggregated previously at 63°C for 1 h (HA-bIgG2). Briefly, cells were incubated with HA-bIgG2 (40 g/ml) for 1 h at 4°C, washed twice with FACS buffer, and incubated for 30 min with a murine mAb to bIgG2 (murine IgG1; Serotec). Cells were again washed twice prior to a final incubation of 30 min with a goat anti-mouse IgG1-FITC conjugate (Southern Biotechnology). Following a final wash, cells were analyzed as above. Data acquisition was conducted with CELLQuest software (Becton Dickinson), whereas analysis was performed with WinMDI software (available from The Scripps Research Institute, La Jolla, CA).
RESULTS

Expression and Ligand Binding Characteristics of bFc␥2R-
Bovine neutrophils have previously been shown to express a specific FcR for bIgG2. This receptor has been identified as bFc␥2R, and a murine mAb of the IgM isotype (CC-G24) has been raised.
2 CC-G24 bound specifically to bFc␥2R expressed at high levels on bovine neutrophils (Fig. 1, panel A) . CC-G24 was also able to specifically block binding of HA-bIgG2 to bovine neutrophils ( Fig. 1, panel B) . HA-bIgG2 was shown to almost completely inhibit binding of bIgG2-coated beads to purified bovine neutrophils; this suggested that bFc␥2R was the only relevant receptor for bIgG2 expressed by these cells (Fig. 1, panel C) . CC-G24 also efficiently recognized bFc␥2R expressed transiently on the surface of COS-1 cells (Fig. 1, panel D) . Using Fugene 6 we routinely obtained transfection efficiencies in the range of 15 to 40% (as measured by either CC-G24 or HA-bIgG2 binding), which was considered sufficient for our FACS-based bIgG2 binding assay. For rosetting analysis, however, we decided to enrich for bFc␥2R-expressing cells. Naturally we could not use mAb CC-G24 to identify bFc␥2R-expressing COS-1 cells, because this mAb binds to the EC1 domain and blocks bIgG2 binding (see panels B and F, and see Ref. 18) . Therefore, to select for cells that had taken up DNA, COS-1 cells were co-transfected with the bFc␥2R plasmids and a vector encoding GFP (Fig. 1 , panel E). Our initial experiments using this co-transfection protocol demonstrated that the COS-1 cell population expressing the highest level of GFP (and therefore being the most fluorescent) contained the highest percentage of bFc␥2R-positive cells (data not shown). Therefore, a gate was defined (see Fig. 1 , panel E) that allowed the purification of the COS-1 cells with the highest fluorescence intensity. For the wild type bFc␥2R, we found that 70 -90% of the (GFP ϩ ) cells purified according to the above protocol also expressed bFc␥2R, as assessed by their ability to bind bIgG2-coated beads ( Fig. 1, panel F) . Furthermore, prior incubation of bFc␥2R ϩ / GFP ϩ COS-1 cells with mAb CC-G24 almost completely abolished binding of these cells to bIgG2-coated beads ( Fig. 1, 
panel F).
Design, Construction, and Expression of bFc␥2R MutantsBovine Fc␥2R is a member of the Ig gene superfamily of proteins and is closely related to several human members of this family, including the KIRs, Ig-like transcripts, and the human Fc␣R (CD89) (14) . Several three-dimensional structures of KIR proteins have now been described, thus identifying the secondary structure composition of the Ig domains. Therefore, because of the highly conserved nature of the Ig-like domain structure, an amino acid alignment of the Ig domains of KIR and bFc␥2R was generated (Fig. 2) . When the relative positions of the KIR ␤-strands were superimposed on this alignment the conservation of residues in comparable regions of bFc␥2R was apparent. Because clustering of conserved residues in areas of structural significance may indicate a common Ig domain structure, these regions also likely form ␤-stranded secondary structures in bFc␥2R (and probably other family members). In addition, it is now recognized that amino acids that form ligand binding sites within Ig-like domains are predominately located within the loop regions. The ␤-strands, on the other hand, tend to be more involved in the preservation of the overall Ig-like domain structure. It is probably for this reason that amino acids in the loop regions of Ig-like domains tend to be less conserved than those in the strands (see Fig. 2 ). Thus, we initially selected a series of amino acids predicted to lie in and around several putative loop regions of bFc␥2R as targets for mutagenesis. We then introduced three and four amino acid mutations into these regions to reveal which of them might be involved in bIgG2 binding and thus might be candidates for further studies. Regions identified during this first round of screening were further analyzed by the introduction of single base pair mutations. We first introduced a series of three or four amino acid mutations into the B-C, C-CЈ, E-F, and F-G loops, because these were the largest loops and thus the areas of greatest divergence (see Fig. 2 ). The C-CЈ and F-G loops were especially interesting when we considered what was already known concerning the location of ligand binding sites within other members of the gene family to which bFc␥2R belongs. The C-CЈ loop has been shown to be important for MHC class I recognition by the p58 KIR, and the F-G loop is reported to contain the IgA binding site of CD89 (21, 23) . A further mutant was generated by deleting part of the (elongated) bFc␥2R EC1-EC2 linker region (the E-R del mutant), to study its contribution (if any) to bIgG2 binding. This mutant was constructed, because recent structural data have shown that the angle of the hinge between EC1 the EC2 domains of the KIR proteins can vary (possibly influencing ligand binding and function), and may partly depend on the composition and length of this linker region.
The bIgG2 Binding Site of bFc␥2R Lies in the F-G LoopMutant bFc␥2R cDNAs transfected to COS-1 cells were analyzed by FACS for surface expression, as measured by binding of the bFc␥2R-specific mAb CC-G24. At the same time, the expressed receptors were analyzed for their ability to bind small HA-bIgG2 complexes in solution, also by flow cytometry (see "Materials and Methods"). Analysis of the panel of EC1 domain mutants showed that only mutations in and around the F-G loop region of this domain influenced bIgG2 binding (Fig.  3) . Mutation of amino acids SHF at positions 80 -82 and VWN at positions 85-87 abolished binding of HA-bIgG2. Mutations in the B-C loop (NTK; positions 35-37), the C-CЈ loop (KEGD; positions 43-46), and the E-F loop (NVRE; positions 68 -71) did not affect HA-bIgG2 binding. It is interesting to note, however, that whereas the NVRE mutant could bind HA-bIgG2, it was apparently not recognized by the bFc␥2R-specific mAb CC-G24. The number of cells transfected with the KEGD mutant detected by mAb CC-G24 was also reduced (compared with those positive with HA-bIgG2). Together, these observations suggested that the epitope recognized by mAb CC-G24 lies close to, or within, the E-F loop. In addition, our data also suggest that the epitope for this mAb may also include, to a lesser extent, part of the C-CЈ loop.
Our first round of mutagenesis experiments thus identified several stretches of amino acids important for bIgG2 binding. Mutation of amino acids SHF (position 80 -82) and VNW (position 83-85) to alanine both produced mutant bFc␥2R molecules that were expressed at the cell surface but unable to bind bIgG2 (Fig. 3A) . Our data therefore suggested that residues within the F-G loop region were necessary for binding of bIgG2. We next selected four additional amino acids within these regions for further individual mutational analysis. Two of these amino acids are predicted to lie at the beginning of the F-G loop (His-81 and Phe-82) whereas the other two lie further along this loop (Asn-86 and Trp-87) (see Fig. 2 ). Asn-86 was also interesting from a structural point of view, because it lies within a possible N-glycosylation addition sequence (Asp-XSer/Thr or N-X-(S/T) with the one letter code; see Fig. 2 ). It is well known that changes in the glycosylation patterns of proteins can adversely affect their expression and function. Results, however, demonstrated that the N86A mutant was expressed at the cell surface and readily able to bind HA-bIgG2. Similarly, the H81A mutant was also expressed at the cell surface and able to bind HA-bIgG2. Conversely, we found that even though the F82A and W87A mutants were indeed expressed on the cell surface, they proved entirely unable to bind to HA-bIgG2 (Fig. 3B) .
The consequences of deleting the linker region between the EC1 and EC2 domains of bFc␥2R (the E-R del mutant) were more difficult to interpret. Although our FACS-based assays showed that this mutant was not recognized by the mAb CC-G24, we did detect a small percentage of cells able to bind HA-bIgG2.
Rosetting analysis was used to confirm the binding ability of the various bFc␥2R mutants. Rossetting with large Ig-coated particles is a more sensitive method of assessing ligand binding because of the higher avidity of the binding interaction. In our rosetting assay we pre-selected COS-1 cells that expressed transfected DNA at high levels by co-transfection of a plasmid encoding GFP (see "Materials and Methods"). Our results confirmed that residues within and surrounding the F-G loop were critical for bIgG binding (Fig. 4) . In addition, rosetting confirmed that the E-R mutant was functionally expressed on the cell surface (albeit on a low number of cells) and readily able to bind bIgG-coated beads.
DISCUSSION
By generating and expressing a panel of bFc␥2R proteins carrying specific mutations within their membrane-distal EC1 domains, we have identified residues essential for forming the bIgG2 binding site. Several amino acids located immediately prior to the predicted start of the F-G, loop as well as residues within the loop itself, were shown to be critical for bIgG2 binding. In particular we found that mutation of either Phe-82 or Trp-87 to alanine completely abolished binding to bIgG2.
Introduction of point mutations into the loop regions of FcRs and Igs has provided a great deal of information regarding their structure and function (19) . These proteins are composed of several globular domains linked by extremely variable stretches of amino acids that make up the flexible loop regions. Thus, mutagenesis of residues within these loop regions probably does not adversely disturb native protein structure. Importantly, the majority of bFc␥2R mutants described here were still able to efficiently bind bIgG2 and were still recognized by an anti-bFc␥2R mAb. Even when the mAb recognition site was disrupted (in the NVRE and KEGD mutants) these receptors were still able to bind bIgG2. Furthermore, the mutants that were unable to bind bIgG2 were still recognized by the mAb. Therefore, we feel that mutagenesis of residues within the EC1 domain of bFc␥2R are unlikely to have adversely affected overall protein structure, allowing assessment of the relative contribution of the mutated residues to the bIgG2 binding site.
We also chose to delete the stretch of amino acids that forms the linker region between the EC1 and EC2 domains of bFc␥2R. The linker region of bFc␥2R is longer than in other related receptors and may have a structural significance. Thus deletion of this region may have more severe consequences for the overall structural integrity of this receptor. Our results showed that whereas surface expression of the E-R del mutant could not be detected by the anti-bFc␥2R mAb, a small proportion of transfectants were still able to bind bIgG. One explanation for these observations could simply be that the E-R del mutant was only expressed by a few cells (because of low transfection efficiency) but when expressed was readily able to bind bIgG2. However, an alternative explanation may be that deletion of the EC1-EC2 linker region results in an aberrantly folded protein unable to be expressed with the correct conformation at the cell surface. The few cells detected in our assay may result from surface expression of incorrectly assembled bFc␥2R molecules where the bIgG binding site is still exposed.
FIG. 2. Alignment of the protein sequences of bFc␥2R and p58 KIR (NCBI accession numbers CAA85736 and P43626, respectively). ␤-Sheet regions of the KIR EC1 domain (designated
Bovine Fc␥2R is closely related to a family of human genes found on chromosome 19 within the leukocyte receptor complex (LRC) that includes the KIR, monocyte/macrophage Ig-like receptor, Ig-like transcripts/LIR, and CD89 proteins (24, 25) . In support of this close genetic relationship, the bFc␥2R gene has been mapped to bovine chromosome 18, which is reported to correspond to human chromosome 19 (26) . The genes of the LRC are only slightly less closely related genetically to the other mammalian FcRs than they are to each other. Moreover, available crystal data suggest that proteins encoded in the LRC are structurally quite similar to FcRs (Fc␥RII, III, and Fc⑀RI) (14) . However, despite this high degree of homology, the location of the ligand binding sites within these molecules varies considerably. The binding site for human IgG within Fc␥RII and Fc␥RIII lies predominantly in the EC2 domain, close to the EC1/EC2 hinge region (27) (28) (29) . A similar EC2 site within Fc⑀RI is important for binding IgE (30, 31) . In both these cases, residues within the F-G loop of the EC2 domain are involved (19) . In contrast, the ligand binding sites within the LRCencoded proteins studied to date have been shown to lie predominantly in the membrane-distal EC1 domains (18, (21) (22) (23) . However, the location of the ligand binding sites varies even among LRC-encoded proteins. The specificity of the p58 KIR protein for its MHC I ligand has been shown to depend on a single residue located in the C-CЈ loop of EC1 (marked with an open triangle in Fig. 2) (21) . More recent data have suggested that additional residues located around the EC1/EC2 hinge region of the KIRs are involved in maintaining high affinity binding to their MHC I ligands. According to the solved crystal structure of the KIR proteins, these residues all lie on the top face of the molecule (22) . On the other hand, ligand binding sites within CD89 and LIR-2 (the only other LRC-encoded proteins yet characterized) are located in a different region of EC1. For both these proteins residues within and around the putative F-G loop are critical for high affinity binding to ligand, whereas exposed residues in other parts of EC1 can also contribute (22, 23, 32) .
Although mutation of residues in and around the F-G loop of the bFc␥2R EC1 domain adversely affected bIgG2 binding, mutations in other putative loops had little affect. Mutation of residues in the predicted B-C loop (NTK mutant), the C-CЈ loop (KEGD mutant), and the E-F loop (NVRE mutant) did not affect bIgG2 binding. Thus mutation of residues around the KIR binding site in the C-CЈ loop had no affect on function. We did, however, notice that mutations introduced into the E-F loop abolished binding of the anti-bFc␥2R mAb CC-G24, whereas mutation of the C-CЈ loop produced receptors that bound the mAb poorly. These results suggest that the epitope for mAb CC-G24 includes (at least partly) the E-F loop region and may also involve (part of) the C-CЈ loop. It is interesting to note that if the three-dimensional structure of bFc␥2R proves to closely resemble that of the KIRs, these two loops would be predicted to lie close together on the top of the EC1 domain (33) .
We also compared the EC1 F-G loop sequence of bFc␥2R with the EC2 F-G loop sequence from other mammalian Fc␥Rs for comparable IgG binding motifs. We noted that all low affinity Fc␥Rs possess a conserved glycine (Gly-156) residue at the beginning of the EC2 F-G loop that is always preceded by a hydrophobic residue (Ile, Phe, Lys, or Val). Both these residues have been implicated in the binding of IgG (19) . A similar motif, Ile-83-Gly-84, is present at a comparable position in the EC1 F-G loop of bFc␥2R. Thus we wondered whether these residues could also play a role in binding to bIgG2. However, our results obtained with the IGV mutant showed that these residues do not contribute to bIgG2 binding.
We also examined the bFc␥2R EC1 F-G loop sequence for similarities with the same region of CD89. Elegant mutagenesis studies with soluble CD89 molecules have shown that Arg-82 and His-85 are essential for IgA binding, whereas Arg-87 makes a minor contribution (23) . Because of the nature of the amino acids involved in binding, it would appear that the CD89-IgA interaction is charge-based. Strikingly, our data demonstrate that amino acids at positions 82 and 87 of bFc␥2R are also essential for ligand binding, although the hydrophobic nature of the residues involved in the bFc␥2R-bIgG2 interaction suggests a different method of binding. Interestingly, as mentioned above, hydrophobic residues are thought to be important for ligand binding by other mammalian Fc␥Rs, perhaps by the formation of a hydrophobic pocket to which the IgG is subsequently bound (19) .
Therefore, it appears that the IgA binding site of CD89 and the bIgG2 binding site of bFc␥2R lie in almost identical areas of the molecules. One may wonder whether this could be explained by the nature of their ligands. It is known that bFc␥2R binds neither bIgG1 nor human IgA (13) . Conversely, bIgG2 binds poorly, or not at all, to other bovine Fc␥Rs (10) . The reason for this may be that bIgG2 carries a 6-amino acid deletion within the lower hinge region at a site considered to form an Fc␥R binding motif within all IgG molecules in which it is present, including bIgG1 (19, 34) . Thus, bIgG2 has clearly evolved an FcR binding site distinct from other mammalian IgG molecules. Therefore, it is extremely interesting to note that the CD89 binding site within IgA is not located in the lower hinge region, as it is with IgG, but rather is located at the C␣2/C␣3 interface (35, 36) . Unfortunately, it is not known where the bFc␥2R binding site of bIgG2 lies, although our results strongly suggest that it may perhaps be located at a similar position to that found in human IgA, i.e. the C␥2/C␥3 boundary.
Altogether, it is likely that the evolution of Ig binding sites within the EC1 domains of bFc␥2R and CD89 are specific adaptations that allow efficient binding to Ig molecules at sites distinct from the lower hinge region. At least for IgA, the C␣2/C␣3 region must be easily accessible to the EC1 domain within all the molecular forms of IgA (monomeric, dimeric, and secretory IgA) and not be obstructed by a J chain or a secretory component, because CD89 is able to bind all monomeric and polymeric forms (37) . A possible reason for the relocation of the FcR binding site in these Ig molecules is that the lower hinge region may be blocked by other parts of the molecule. Supporting this theory is the recent observation that IgA1 may in fact adopt a more "T"-like shape, in contrast to the more "Y" shape more readily associated with IgG molecules, suggesting that the hinge region of IgA1 is (at least partly) obscured by the Fab arms hindering binding to this region (38) . Moreover, molecular modeling of bovine IgG2 predicts that because of the deletion in the hinge region, bIgG2 is a highly compact molecule with a close positioning of the Fab and Fc domains; this would allow only very little or no angular or rotational movement of the Fab arms in relation to the Fc domain (34) . Interestingly, IgA2, the second subclass of human IgA (which readily binds to CD89) also possesses a very short hinge region, and the structure and flexibility of this isotype probably more closely resembles that of bIgG2 (39) .
In conclusion, we have identified residues in and around the F-G loop of the EC1 domain of bFc␥2R that are important for ligand binding. Specifically, we have shown that Phe-82 and Trp-87 are critical for the binding of bIgG2. The bIgG2 binding site of bFc␥2R is similar to the IgA binding site of the closely related human IgA Fc receptor, CD89. It is likely that these binding sites have evolved to ensure efficient ligand binding and effector cell activation by these FcRs. 
